Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of 18F-FCH PET/CT in Prostate Cancer
NCT02840552Phase 3Completed
- Sponsor
- Jewish General Hospital
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluorine-18 fluorocholine in prostate cancer (PCa), sponsored by Jewish General Hospital. Primary endpoints: Incidence of adverse events (AE) at 7 days, Sensitivity and specificity vs CT on a per patient basis at 12 months and 1 more. Started Sep 2016; status: completed.
02
Drugs
fluorine-18 fluorocholine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02840552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840552.